linjc16/ctgov huggingface dataset:
Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysteroscopy Practice

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate that Lidocaine-Prilocaine cream decrease pain during hysteroscopy diagnostic practice.

Official Title
-----------------
Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysteroscopy Practice: a Prospective Randomized Clinical Trial

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: lidocaine-prilocaine cream
* Other: gel application for the transmission of ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients that he must perform a diagnostic hysteroscopy acceptance to participate in the study signed informed consent Exclusion Criteria prerandomization: hypersensitivity or allergy to anesthetics refusal of the patient patients under age 18 and pregnant Exclusion Criteria postrandomization: dropout unbearable pain that involves other analgesic measures allergic reactions to topical anesthetics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Lidocaine-Prilocaine cream<br> | Drug: lidocaine-prilocaine cream<br>* Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.<br>* Other names: EMLA;|
| Placebo Comparator: placebo<br> | Other: gel application for the transmission of ultrasound<br>* 3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5ml syringe without needle. Application, with a swab in gel ectocervix<br>* Other names: Transonic-Gel;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain reduction in the performance of hysteroscopy | decrease in pain immediately after the completion of hysteroscopy and one month after completion of the diagnostic test by an analogue pain scale | after hysteroscopy and a month later | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sense of discomfort experience during the procedure | willingness to repeat the diagnostic technique | a month after hysteroscopy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hysteroscopy, local anaesthetic, pain relief, gynecological pathology
The Natural History and Prognostic Factors of Compensated Cirrhosis.

Study Overview
=================
Brief Summary
-----------------
Study Design and Methodology Study Population:Compensated Cirrhosis Study Design: An Ambi Prospective Cohort study Study Period: 2 Years Sample size: Retrospective- All patients from Jan 2010 to Mar 2017 Prospective- Assuming the incidence of clinical decompensation is 5%/year.With alpha of 5%, power 80% we need to enroll 138 cases. Further assuming 20% drop out 166 cases will be enrolled. Intervention: This is an observational study. No intervention will be given. Monitoring and assessment: All the routine investigation and clinical information will be collected at 6, 12,18 and 24 months.

Official Title
-----------------
The Natural History and Prognostic Factors of Compensated Cirrhosis: An Ambi Prospective Cohort Study

Conditions
-----------------
Compensated Cirrhosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 to 75 years Compensated cirrhosis Biopsy proven cirrhosis or LSM > 12.5 Kpa. Exclusion Criteria: Any current or prior clinical decompesnation (ascites, jaundice, encephalopathy or gastrointestinal hemorrhage). Pregnant Women Hepatocellular Carcinoma Known case of severe cardiopulmonary disease Known case of severe Hepato Pulmonary Syndrome

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Compensated Cirrhosis<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of ascites, jaundice, encephalopathy or gastrointestinal hemorrhage) during the follow up period of 2 yeas |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients with new onset/progression of esophageal varices during the period of 2 years |  | 2 years | 
| Reduction in portal pressure with >20% from baseline at 6 months |  | 6 months | 
| Reduction in portal pressure with >20% from baseline at 1 year |  | 1 year | 
| Reduction in portal pressure with >20% from baseline at 2 year. |  | 2 year | 
| Survival during the period of 2 years. |  | 2 years | 
| Number of patients develop hepatocellular carcinoma (HCC) during follow up period 2 years. |  | 2 years | 
| Number of patients develop Pulmonary Syndrome (HPS) during follow up period of 2 years. |  | 2 years | 
| Number of patients develop Minimal Hepatic Encephalopathy (MHE) during follow up period of 2 years. |  | 2 years | 
| Number of patients develop Hypersplenism during follow up period of 2 years. |  | 2 years | 
| Number of patients develop Hepatic osteodystrophy during follow up period of 2 years. |  | 2 years |
Egyptian Women Knowledge and Use of Different Contraceptive Methods

Study Overview
=================
Brief Summary
-----------------
Starting from Jan 2012 for an interval of 4 months with minimum number of 1200 egyptian women will be asked to complete a questionairre to evaluate their knowledge of different contraceptive methods

Detailed Description
-----------------
PATIENTS AND METHODS Sample size, Time of the study: Starting from Jan 2012 for an interval of 4 months with minimum number of 1200women . Type of the study: Analytical crossectional study Place of the study: Ain Shams University Hospital, Gynecological outpatient clinic and Amireya primary care medical center (family planning clinic). Statistical methodology: SPSS program will be used for data analysis. Appropriate significance tests will be used according to type of data. After an oral consent is taken from them, Women will be asked to complete a short written questionnaire that includes social data, reproductive information, and some questions about common contraceptive methods. Testing readability and comprehension of the questionnaire will be done first by collecting 50 questionnaires and analyzing the data. AIM OF THE WORK The aim of this study is to evaluate knowledge and use of different available contraceptive methods among women attending Ain Shams University maternity hospital in the gynecological outpatient clinic and Amireya primary care medical center (family planning clinic).

Official Title
-----------------
Egyptian Women Knowledge and Use of Different Contraceptive Methods

Conditions
-----------------
Contraception

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age : 18 -51 years old Using a contraceptive method for at least 6 months continuously. Exclusion Criteria: Infertile Vaginal bleeding of unknown etiology. Current pregnancy Menopausal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 51 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| knowledge of the different contraceptive methods | subjects answer the questionairre correctly or at least 70% right answers | march 2012 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correct use of different contraceptive methods | assessing that the subjects use contraceptive methods in correct way based on their knowledge | march 2012 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
contraception, family planning, egyptian, knowledge
Nevada Environmental Tobacco Smoke and Health Study

Study Overview
=================
Brief Summary
-----------------
Workplace exposure to secondhand cigarette smoke or environmental tobacco smoke (ETS)is widespread, effecting between 19 and 49% of the U.S. workforce. The first part of this study is designed to test whether exposure to ETS in the workplace effects a person's risk of developing chronic diseases such as cardiovascular disease and cancer. The second part of this study is designed to test whether antioxidant supplementation in this group of ETS exposed individuals can reduce their risk of developing chronic disease. The study will look at 375 non-smokers who either work on a casino floor or as bartenders or cocktail servers. Initial baseline data will be collected (questionnaires and blood samples taken) and the subjects will be randomized into one of three groups, placebo, low antioxidant supplementation and high antioxidant supplementation. They will be followed over a two-year period, coming in for follow-up testing every six months. Statistical analysis will be conducted to see whether this group of ETS exposed individuals has a greater risk of developing chronic disease and whether the use of antioxidant supplements can moderate any risks.

Conditions
-----------------
Cardiovascular Disease, Cancer

Intervention / Treatment
-----------------
* Drug: Antioxidants


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-smoker Work in a casino - on the casino floor or work as a bartender or cocktail server for at least 1 year Do not take antioxidant supplements Healthy - not diagnosed with any major chronic diseases. Exclusion Criteria: Blood pressure SBP>200,<85 DBP>100, <40 Pulse >120, <45 Cholesterol >400 Triglycerides >700 Blood Cotinine >10 ng/ml BMI >35

Ages Eligible for Study
-----------------
Minimum Age: 22 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Antioxidants|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oxidative Stress, Cardiovascular Disease, Cancer
Reproducibility of Cirrus Optical Coherence Tomography Measurements

Study Overview
=================
Brief Summary
-----------------
In this study the reproducibility of optical coherence tomography measurements should be evaluated.

Official Title
-----------------
Reproducibility of Retinal Thickness and Volume Measurements Determined With the Cirrus Spectral Domain OCT

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Device: Cirrus™ HD-OCT, Carl Zeiss Meditec AG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older best corrected visual acuity of at least 20/25 clear optical media Exclusion Criteria: any kind of retinal pathology any kind of opacity of optical media any kind of intraocular surgery spherical refraction of more than 5 diopters cylindrical refraction of more than 3 diopters amblyopia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observation<br> | Device: Cirrus™ HD-OCT, Carl Zeiss Meditec AG<br>* the retinal thickness and volume is determined on two different days with the Cirrus™ HD-OCT.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| retinal thickness |  | two | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| retinal volume |  | two | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
normal eyes
Detecting Dementia in the Retina Using Optical Coherence Tomography

Study Overview
=================
Brief Summary
-----------------
This retrospective case control explores the retinal features of dementia associated with neurodegenerative diseases, particularly Alzheimer's disease. By linking a pseudonymised dataset of three-dimensional retinal scans, called optical coherence tomography, with nationally held data on dementia, corresponding characteristics will be evaluated through descriptive statistics and machine learning techniques.

Detailed Description
-----------------
By 2025, it is estimated that approximately 1 million people in the United Kingdom (UK) will suffer from dementia, a syndrome associated with progressive decline in brain function. While there is currently no cure for most types of dementia, early diagnosis can help patients receive the appropriate treatment and support to help maintain mental function. The focus of this project is to identify changes in retinal structure associated with dementia. In collaboration with bioinformatics experts at University College London (UCL), the investigators propose to analyse our repository of >1 million retinal scans, termed optical coherence tomography (OCT), performed regularly on patients since 2008. OCT scans will be linked at a patient level to data from the Hospital Episode Statistics (HES) database to identify those who have been diagnosed with dementia or went on the develop dementia. Thus, a pseudonymised classified dataset of retinal scans will be generated for qualitative and quantitative analysis. The primary objective is to characterise changes in the layers of the retina associated with dementia. Machine learning techniques may also be employed to identify novel patterns of retinal change associated with dementia.

Official Title
-----------------
Detecting Dementia in the Retina: a Big Data Machine Learning Approach

Conditions
-----------------
Dementia Alzheimers, Dementia, Dementia, Vascular, Dementia Senile

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients over the age of 40 who have undergone an optical coherence tomography scan at Moorfields Eye Hospital NHS Foundation Trust Exclusion Criteria: Poor quality image

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Dementia<br>People with hospital episode statistics labels of dementia | |
| Normal<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal nerve fiber layer thickness |  | 1 year | 
| Ganglion cell layer thickness |  | 1 year | 
| Macular volume |  | 1 year |
Investigation of Metabolic Risk in Korean Adults

Study Overview
=================
Brief Summary
-----------------
A cohort study with Korean adults to investigate biomarkers in prediction of cardiometabolic and other diseases

Detailed Description
-----------------
This is a prospective cohort study with Korean adults to investigate biomarkers in prediction of cardiometabolic and other diseases

Official Title
-----------------
Investigation of Metabolic Risk in Korean Adults

Conditions
-----------------
Cardiovascular Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adults without chronic diseases Diabetic patients who are well controlled with oral antidiabetic agents Hypertensive patients who are well controlled with oral antihypertensive agents Dyslipidemic patients who are well controlled with oral lipid-lowering agents Exclusion Criteria: Malignancy Chronic wasting disease Long-term steroid use

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal cohort<br>Normal cohort for biobank | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of cardiovascular disease |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of diabetes mellitus |  | 5 years | 
| Incidence of fatty liver |  | 5 years | 
| Incidence of metabolic syndrome |  | 5 years | 
| Incidence of osteoporosis |  | 5 years | 
| Incidence of sarcopenia |  | 5 years |
A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical research study is to learn if BMS-582949 alone is an effective treatment for moderate to severe psoriasis. The safety of the drug and the effectiveness of each dose will also be studied.

Official Title
-----------------
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Three Different Doses of BMS-582949 Given Orally to Subjects With Moderate to Severe Plaque Psoriasis

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Drug: BMS-582949
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and Females (not nursing or not pregnant) 18-75 years of age Diagnosis of moderate to severe psoriasis for at least six months at the time of screening Subjects will require wash-out of certain therapies for the treatment of psoriasis but will be allowed to continue on certain topical therapies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A1<br>10 mg | Drug: BMS-582949<br>* Tablets, Oral, Once daily, 12 weeks<br>|
| Active Comparator: A2<br>30 mg | Drug: BMS-582949<br>* Tablets, Oral, Once daily, 12 weeks<br>|
| Active Comparator: A3<br>100 mg | Drug: BMS-582949<br>* Tablets, Oral, Once daily, 12 weeks<br>|
| Placebo Comparator: P1<br>10 or 100 mg | Drug: Placebo<br>* Tablets, Oral, Once daily, 12 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary endpoint is the proportion of subjects achieving an IGA score of clear or almost clear at Week 12 |  | at Week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of subjects achieving a PASI-50 |  | at Week 12 | 
| Proportion of subjects achieving a PASI-75 |  | at Week 12 | 
| Proportion of subjects achieving a PASI-90 |  | at Week 12 |
Is the Distance of Patients From Rouen University Hospital Influencing the Time Between Colectomy and First Chemotherapy Cure for Colon Cancer?

Study Overview
=================
Brief Summary
-----------------
This project has for objective to demonstrate that the increase of the distance Patient home - center of treatment may be associated with significant, other noticeable, noted events. This distance may also be available in the Rouen University Hospital. The study of the association in this distance and the delay in initiating chemotherapy after surgery in patients treated at the CHU correspond to a pilot study prior to the completion of the analysis at the regional scale.

Official Title
-----------------
Is the Distance of Patients From Rouen University Hospital Influencing the Time Between Colectomy and First Chemotherapy Cure for Colon Cancer?

Conditions
-----------------
Cancer Colon, Colectomy, Chemotherapy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients who had colectomy for colon cancer and at least one chemotherapy treatment at CHU Rouen, between 2009 and the first half of 2015. Exclusion Criteria: Patients who died in hospital before receiving a chemotherapy treatment Patients with a CIM code of metastasis during the stay of the colectomy or the first chemotherapy treatment Patients who received a chemotherapy treatment before colectomy Patients who have undergone several colectomies.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| distance home of patients - treatment center | Analyze the influence of distance home of patients - treatment center on the compliance of the time between colectomy and initiation of CTa | At the inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
distance